Effect of the purified unsaponifiable fraction of soybean on primary type II hyperlipoproteinemia.
We evaluated the large dose effect of the purified unsaponifiable fraction of soybean (PUFS) given over 24 weeks to 19 patients with primary types IIa and IIb hyperlipoproteinemia. The percent reduction of plasma cholesterol in types IIa and IIb were 13.2% and 11.5%, respectively. PUFS significantly reduced LDL cholesterol levels, but had little affect on VLDL or HDL cholesterol. The triglyceride/cholesterol ratio in HDL fraction was also significantly reduced, suggesting that PUFS plays a role in the catabolism of HDL. PUFS contained tocopherol and unsaturated fatty acid. The relative impact of the individual components could not be assessed directly, however, it seemed reasonable to conclude that the hypo-cholesterolemic effect of PUFS results from a summation effect of plant sterols, tocopherols and unsaturated fatty acids.
D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D010840:Phytosterols / Q000627:therapeutic use*; D013025:Glycine max; D014280:Triglycerides / Q000097:blood
D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D010840:Phytosterols; D014280:Triglycerides; D002784:Cholesterol